Abstract: During embryogenesis and development, the fetus obtains oxygen and nutrients from the mother through placental microcirculation. The placenta is a distinctive organ that develops and differentiates per se, and that organizes fetal growth and maternal condition in the entire course of gestation. Several life-threatening diseases during pregnancy, such as pregnancy-induced hypertension (PIH) and eclampsia, are closely associated with placental dysfunction. Genetic susceptibilities and poor placentation have been investigated intensively to understand the pathophysiology of PIH. It is currently thought that "poor placentation hypothesis", in which extravillous trophoblasts fail to invade suffi ciently the placental bed, explains in part maternal predisposition to this disease. Cumulative studies have suggested that hypoxic micromilieu of fetoplacental site, shear stress of uteroplacental blood fl ow, and aberrantly secreted proinfl ammatory substances into maternal circulation synergistically contribute to the progression of PIH. For example, soluble form of vascular endothelial growth factor receptor-1 (sVEGFR-1) and soluble form of CD105 are elevated in circulation of PIH mothers. However, it remains to be poorly understood the pathological events in the placenta during the last half of gestation as maternal systemic disorders get worse. For better understanding and effective therapeutic approaches to PIH, it is important to clarify pathological course of PIH-associated changes in the placenta. In this review, current understanding of placental development and the pathophysiology of PIH placenta are summarized. In addition, recent fi ndings of vasoactive signalings in PIH and rodent PIH models are discussed.
Introduction
The placenta starts organogenesis in the very early stage of embryogenesis, governs fetal growth, and terminates its own fate immediately after delivery. Placental perfusion is maintained by two distinct cardiovascular systems, ie, maternal blood fl ow and fetal circulation. Therefore, pathophysiology of the placenta is closely associated with both maternal status and fetal development. Among pregnancy-associated complications, eclampsia is an emergency condition for both mother and fetus. To prevent the lethal disaster, it is mandatory to care properly the patients in preeclamptic condition, ie, pregnancy-induced hypertension (PIH). PIH is characterized by blood pressure elevation after 20 weeks of gestation that is often accompanied by proteinuria (NHBPEP 2000) . Genetic, immunologic, metabolic susceptibilities and other backgrounds have been investigated to understand the pathogenesis of this disease (Hiby et al 2004; van Dijk et al 2005; Hu et al 2006; Johnson et al 2007) . Several important fi ndings have contributed to our understanding of maternal genetic predisposition, eg, specifi c patterns of genetic variant of angiotensinogen gene and quantitative trait loci on some chromosomes including 5q, 10q, and 13q (Morgan et al 1997; Kobashi et al 1999; van Dijk et al 2005; Johnson et al 2007) . Both background and progression course of PIH vary among cases, and it is diffi cult to predict whether the condition is improved in response to treatment or is aggravated and resulted in preterm termination. Currently, the onset of PIH is considered to depend not only on a sole or a few pathological events. It may rather be triggered by a load of predisposing factors that potentially promote circulatory dysfunction (Redman and Sargent 2005) .
Wide variety of angiogenic molecules and proteolytic enzymes play critical roles in the establishment of placentation and development of placental circulatory system (Adamson et al 2002; Kharfi et al 2003; Reynolds et al 2005) . For example, vascular endothelial growth factor (VEGF), fi broblast growth factor (FGF), and placenta growth factor (PlGF) are indispensable in the entire course of gestation (Reynolds and Redmer 2001; Zygmunt et al 2003) . In later stages of pregnancy, villous trophoblasts and fetal-side blood vessels of terminal villi (or labyrinth in mouse placenta) form fi nely-differentiated vascular network to serve a fetus with suffi cient amounts of oxygen and substances for exponential fetal growth (Reynolds et al 2005) . The arterial circulation in the placenta lacks autonomic innervation and is regulated by local signals such as pressure and fl ow (Myatt 1992) . If implantation process is not performed successfully, the placenta suffers from insuffi cient perfusion and secretes various kinds of proinfl ammatory molecules that damage maternal endothelial cells (ECs), and in consequence, vascular resistance is increased that further burdens maternal organs with hypertension as well as aggravates fetoplacental milieu (Kharfi et al 2003; Karumanchi and Bdolah 2004; Redman and Sargent 2005) .
It is thought that systemic infl ammatory response and dysfunction of maternal ECs represent the pathological scheme of PIH (Granger et al 2001; Karumanchi and Bdolah 2004; Redman and Sargent 2005) . Various proinfl ammatory cytokines/peptides including serological markers soluble form of VEGF receptor-1 (sVEGFR-1, also named sFlt-1) and soluble form of CD105 (sCD105, also named soluble form of endoglin) are elevated in PIH mothers, and these anti-angiogenic factors are thought to play critical roles in maternal ECs-dysfunction (Granger et al 2001; Maynard et al 2003; Venkatesha et al 2006) . On the other hand, it is poorly understood the pathological courses of the placenta and the mechanisms that lead to intrauterine growth restriction (IUGR) of the fetus. With regard to placental dysfunction, since very limited examinations are available for pregnant patients, the analysis of placental circulation is based mainly on Doppler studies and on the pathological investigation of terminated placentas (Ohkouchi et al 2000; Parretti et al 2003; Kraus et al 2004) . The dynamics of vasoactive signalings in the placenta during upsurge of blood pressure remain enigmatic.
In this review, placental development and proinfl ammatory microenvironments of PIH are discussed. First, general structure of the placenta in human and mouse is summarized. Second, current understanding of pathological events of the placenta in PIH is overviewed. Third, the findings obtained from PIH model mice are introduced, and possible pathological events occurred to fetoplacental vasculature under preeclamptic condition are discussed.
Structure of placental vascular network
Both in human and mouse, a normal term placenta is divided largely into three layers ( Figures 1A, 1B) : (1) Basal plate (maternal surface) and anchoring villi (most distal extensions of the primary stem villi) that interact directly with maternal endometrium. (2) Terminal villous unit (human) or labyrinth (mouse) where gas/nutrients exchange is taken place actively. (3) Chorionic plate (fetal surface) and stem villi that consist of dense connective tissue containing fetal vessels. Amnion and the underling chorion are membranes that cover chorionic plate, and the umbilical cord collects chorionic arteries and veins on chorionic plate generally in the center part (Kraus et al 2004) .
Fundamental structure of the placenta is established during the fi rst half of gestation (Reynolds et al 2005) . In human placenta ( Figure 1A ), terminal villus unit (tertiary villus that stems from secondary villus) is composed mainly of fetal-side capillaries lined by ECs, mesenchymal collagen and outlining syncytiotrophoblasts. In earlier stages, cytotrophoblasts lie beneath syncytiotrophoblasts. As the pregnancy progresses, cytotrophoblasts layer become almost undetectable, and fetal capillaries are placed in close proximity to intervillous maternal circulation, probably for the purpose of effi cient gas/nutrients exchange (Lewis and Benirschke 1997; Kraus et al 2004) . It is of note, that maternal blood space is lined directly by terminally-differentiated syncytiotrophoblasts, not by ECs (hemochorial interface) (Rossant and Cross 2001; Kraus et al 2004) .
Basic architecture of mouse placenta is almost similar to that of human, but there are some differences at microscopic level ( Figure 1B ). In the "labyrinth", both fetal chorionic branches and maternal blood sinusoids are tortuous and exhibit similar dimensions. Blunt-end villi are not detectable. Therefore, it is diffi cult to distinguish microscopically fetal-side blood flow from that of maternal-side without a help of immunohistochemistry. Between fetal and maternal circulatory interface, there are three trophoblast layers (trichorial); ie, two syncytiotrophoblast layers surrounding fetal-side ECs, and a single mononuclear trophoblast facing to maternal blood sinus (Rossant and Cross 2001; Georgiades et al 2002; Adamson et al 2002 ) .
Fetal weights increase almost twice during the last stage (Cunningham et al 1989) . On the other hand, the weight of the placenta does not increase signifi cantly in later stages. Instead, vascular networks in terminal villi/labyrinth become further differentiated and they increase functional capacity of fetal-side capillaries as well as of maternal blood sinuses (Reynolds et al 2005; (Figure 2 ). In IUGR, however, terminal villous differentiation is often disturbed, and the truncation of distal villi becomes evident (Kraus et al 2004) (Figure 6, center) . This pathological course is often accompanied by PIH. Under hypoxic condition, blood fl ow of fetal body accumulates to the most critical organs such as the brain and the heart. This blood redistribution further reduces placental fl ow and increases vascular resistance (Hecher et al 1995) . 
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Figure 2 Development of vascular networks in the labyrinth between E13 and E19. Both fetal vessels (CD31) and maternal blood sinuses (CK) become complicated as gestation progresses . Abbreviation: CK, cytokeratin.
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The early stage of pregnancy:
Epithelial-endothelial transformation
It is well known that during implantation, extravillous trophoblasts invade uterine endometrium and also inner third of myometrium (Kraus et al 2004; Lyall 2005) . To establish suffi cient blood fl ow from maternal circulation, invasive trophoblasts undergo ECs-like specialization. Invasive trophoblasts turn to express some ECs markers such as CD31, VE-cadherin, VCAM-1, and αvβ3 integrin (Zhou et al 1997 (Zhou et al , 2002 . In addition to αvβ3 integrin, these trophoblasts up-regulate the expression of α5β1 and α1β1 integrins and down-regulate the expression of α6β4 integrin (Lyall et al 2001) . This process is called "epithelial-endothelial transformation" or "pseudo-vasculogenesis" (Damsky and Fisher 1998) . A similar process of vascular remodeling has been reported in cancer neovascularization. In several types of malignancies, such as aggressive melanoma, ovarian, prostatic, and breast carcinomas, tumor cells themselves build blood sinus, known as "tumor vasculogenic mimicry" ( . Cancer invasion is destructive and disorganized, whereas trophoblasts invasion is fi nely controlled by local proinfl ammatory microenvironments under physiological condition. Uterine constituents including decidual cells and immune cells govern uteroplacental interaction not only to accept "allogenic" cells, but also to restrict excessive invasion. Pathological feature of impaired epithelial-endothelial transformation in PIH is discussed later.
Proinfl ammatory microenvironments of implantation site
Microenvironments of the uteroplacental junction are crucial for the process of implantation and fetal development throughout gestation. Although the function of uNK cells is not fully characterized, they are thought to play important roles in (1) decidual reaction, (2) remodeling of spiral arteries in the decidua, and (3) immune regulation of trophoblasts invasion (Moffett and Loke 2006; Pijnenborg et al 2006) . In mouse pregnancy, uNK cells are accumulated to implantation site by 10.5 days of gestation (E10.5), and these uNK cells infi ltrate the media of spiral arteries (Adamson et al 2002) . These immune cells contribute to the establishment of blood fl ow from maternal circulation to the placenta in cooperation with invasive trophoblasts by remodeling spiral arteries (Fig 3) . Among various forms of trophoblasts, only extravillous trophoblasts express major histocompatibility complex (MHC) class I molecules (Moffett and Loke 2006) . In human pregnancy, these trophoblasts express human leukocyte antigens (HLA)-C, HLA-E, and HLA-G, a unique repertoire of ligands for uNK cell receptors (King et al 2000a (King et al , 2000b Moffett and Loke 2006; Moffett and Hiby 2006) . HLA-A and HLA-B, the classical MHC class I molecules with polymorphism that initiate allograft rejection, are not expressed in extravillous trophoblasts. Neither MHC class II is expressed (Moffett and Loke 2006) . It is also of note that in fetoplacental site, syncytiotrophoblasts express no MHC antigens on cell surface (Moffett and Loke 2006) . 
Pathophysiology of placentation abnormalities in pregnancy-induced hypertension
There are more than one pathways that control uNK cells function. uNK cells have both stimulatory and inhibitory surface receptors including NKG2 family (CD94), 2B4 (CD244), and NKp46 (CD335) (King et al 2000a; Vacca et al 2006) . For example, the HLA-E in trophoblasts interacts with NKG2A in uNK cells (King et al 2000a) , which may explain in part the mechanism of suppressed uNK cells cytotoxicity against invading trophoblasts. Activating crosstalk between invasive trophoblasts and uNK cells is also required. As mentioned above, polymorphic MHC class I molecules HLA-A and HLA-B are not expressed in extravillous trophoblasts, but another classical class I molecule HLA-C is present at fi rst trimester (King et al 2000b) . Recent studies on immunogenic background of PIH demonstrated that interaction between HLA-C genotypes of trophoblasts and killer-cell immunoglobulin-like receptor (KIR)-family of uNK cells were implicated in unsuccessful pregnancies (Hiby et al 2004) . Hybi and colleagues (2004) found that the combination of fetal HLA-C2 haplotype and maternal KIR-AA genotype resulted in increased risk of PIH. The mechanism is explained as follows; interaction between KIR-A haplotype and HLA-C2 haplotype renders strong inhibitory signal of uNK cells, whereas KIR-B haplotype has an activating receptor for HLA-C haplotype, which increases infl ammatory property of uNK cells (Hiby et al 2004) . Taken together, fi ne tuning of pro-and antiinfl ammatory microenvironments of uteroplacental site is mediated by the crosstalk between maternal-side immune cells and fetal-side invasive trophoblasts, and that certain immunogenetic properties may determine the unfavorable process of pseudovasculogenesis.
Predisposing condition of PIH in the early stage of gestation
As mentioned above, it is generally accepted that poor placentation is an important predisposing condition for the pathophysiology of PIH. The combination of maternal KIR-AA genotype in uNK cells and fetal HLA-C2 haplotype in extravillous trophoblasts significantly increased the susceptibility rate of PIH (Hiby et al 2004) , suggesting that a failure of proper activation of uNK cells leads to insuffi cient trophoblasts invasion. Narrowed blood canals due to poor placentation make the placenta hypoxic, and in response, a series of proinfl ammatory factors are released from the placenta that damage maternal circulatory system. This two stage model, ie, poor placentation of early gestational period (stage I) and maternal systemic dysfunction in later period (stage II), has been widely recognized as a mechanism for the development of PIH (Redman and Sargent 2003; Robert and Gammill 2005) . However, impaired pseudovasculgenesis is unlikely to be an exclusive cause of the disease, and not a few cases show normal gestational process in spite of restricted placental fl ow, and vice versa (Redman and Sargent 2003) .
Key molecules implicated in the pathophysiology of PIH
There are a wide variety of factors that potentially accelerates vasoconstriction of maternal blood vessels. Neurokinin-B, a family of peptides tachykinins, was at fi rst presented to be a responsible molecule that causes PIH (Page et al 2000) . Later studies using large number of samples by different groups, however, have demonstrated controversial results (Schlembach et al 2003) . Currently, it seems not to be fully approved the notion that neurokinin-B functions as a causative agent of PIH. Recent studies by Pal et al provided us with a new insight about neurokinin-B in the progression of PIH (Pal et al 2006) . They demonstrated that neurokinin-B, with the help of thromboxane A2 (TXA2)-like molecule, down-regulated VEGF, VEGFR-1, and VEGFR-2 in cultured ECs, and suppressed angiogenic activities in vitro. Since it is known that the imbalance between TXA2 and prostacyclin PGI2 is contributed to preeclampsia (Chen et al 1993; Mills et al 2001) , neurokinin-B/TXA2 axis may play some important roles in impaired placental neovascularization. Neurokinin-B is present not only in the maternal sera of PIH but also in those of normal pregnancy, and it is increased as pregnancy progresses (Sakamoto et al 2003) . Further investigation is necessary to clarify whether and how neurokinin-B/TXA2 suppresses VEGF-mediated signalings and contributes to the pathophysiology of PIH in vivo.
Apart from neurokinin-B, sVEGFR-1 has been noted as an important serum marker of PIH patients (Maynard et al 2003) . sVEGFR-1 is an endogenous inhibitor of VEGF and PlGF, and excess sVEGFR-1 causes widespread ECs-dysfunction by interfering with physiological effects of VEGF and PlGF (Kendall et al 1993; Stepan et al 2006) . This phenomenon is observed not only in PIH patients. In cancer patients under antiangiogenic therapies, ie, those who administrated humanized monoclonal antibody bevacizumab specifi cally targeting VEGF or several receptor tyrosine kinase (RTK) inhibitors targeting VEGF-related pathways, show hypertension, proteinuria and edema (Faivre et al 2006; Veronese et al 2006) . The analysis of clinical trials on antiangiogenic therapies has shown that these inhibitors disturb more or less physiological angiogenesis, hematopoiesis, platelet function, and so on (Verheul and Pinedo 2007) . In PIH patients, excess sVEGFR-1 seems to be released from the placenta into maternal circulation (Cudmore et al 2007) .
In addition to sVEGFR-1, several studies confi rm that sera of preeclampsia patients show increased level of sCD105, especially in severe cases named HELLP syndrome (Hemolysis, Elevated Liver enzyme, Low Platelets syndrome) (Venkatesha et al 2006) . CD105 is a cell surface co-receptor for transforming growth factor-1β (TGF-1β) and TGF-3β, and is expressed in ECs and syncytiotrophoblasts (Duff et al 2003; Venkatesha et al 2006) . In cardiovascular system, CD105 is thought to regulate the expression of endothelial nitric oxide synthase (eNOS) and eNOS-dependent vascular tone (Jerkic et al 2004; Santibanez et al 2007) . In preeclamptic condition, sCD105 probably inhibits TGF-1β signalings of vasculature (Venkatesha et al 2006) .
Statistical studies suggest that antiangiogenic milieu in maternal circulation seems to be arranged 2-3 months before preeclamptic symptoms become overt. Increased sVEGFR-1 and sCD105, and decreased PlGF and VEGF are detectable in the middle of second trimester (17-20 weeks of gestation). (Levine et al 2006) . Some studies demonstrated that sVEGFR-1, as well as VEGF and PlGF, was produced in isolated trophoblasts from the placenta in vitro, and the level of sVEGFR-1 in culture medium of trophoblasts from preeclamptic patients was higher than that from normal pregnant women (Ahmad and Ahmed 2004) . It is suggested that VEGF/PlGF axis in villous trophoblasts that face maternal blood fl ow is responsible for the pathophysiology of PIH. Under other pathophysiological conditions such as diabetic retinopathy and cancer, hypoxia generally stimulates angiogenic signalings, eg, hypoxia-inducible factor (HIF)-1α-mediated transcriptional cascade of proangiogenic molecules including VEGF (Semenza 2003) . Currently, it remains poorly understood why hypoxic placenta produces the molecules that suppress angiogenesis in preeclampsia. It is also a subject for future study whether sVEGFR-1 and sCD105 are secreted directly in response to hypoxia or whether some other important regulators, including mechanical stress and vasoactive G protein-coupled receptor (GPCR) cascades, also accelerate the secretion of these anti-angiogenic molecules from the placenta. Recent studies have elucidated the implication of angiotensin II-mediated signalings in excessive production of sVEGFR-1 from the placenta in preeclampsia, which will be discussed later.
Implication of renin-angiotensin system (RAS) in PIH
Renin-angiotensin system (RAS) is one of mastermind signalings that control blood pressure, and this signaling cascade participates not only in vasoconstriction but also in a wide variety of homeostatic activities (Lavoie and Sigmund 2003; Paul et al 2006) . The expression of renin mRNA was detected in human decidua, basal placenta, macrophages, chorioamniotic membrane and vascular smooth muscle cells (VSMCs) (Lentz et al 1989; Jikihara et al 1995; Kalenga et al 1996; Morgan et al 1998) . Angiotensin II receptor type 1 (AT1) was shown to be localized both in villous and extravillous trophoblasts and this AT1 responds to exogenously administrated angiotensin II (Li et al 1998; Cooper et al 1999; Zhou et al 2007) . Functionally, local RAS is thought to participate in the regulation of uteroplacental blood fl ow, prostaglandin synthesis, estradiol secretion, and so on (Kalenga et al 1995; Li et al 1998; Nielsen et al 2000) .
The circulating level of angiotensin II increases as the pregnancy progresses (Zheng et al 2005) . It was revealed that in the circulation of PIH mothers RAS was not increased but rather decreased (Hanssens et al 1991) . Thus RAS has once been considered to be unrelated to the pathophysiology of PIH (Hanssens et al 1991; Kalenga et al 1996) . On the other hand, it is accepted as a classical knowledge that vascular sensitivities to angiotensin II are elevated in preeclamptic women (Gant et al 1973) . The mechanism of elevated angiotensin II sensitivity in PIH remained unanswered for a few decades.
AbdAlla and colleagues (2001) investigated the presence of AT1-bradykinin B2 heterodimers in the platelets and omental vessels of pregnant women. They demonstrated that bradykinin B2 protein level increased in preeclamptic patients, and that AT1-bradykinin B2 heterodimers accelerated GPCR signal transduction. The results strongly suggest that angiotensin II cascades are enhanced in preeclamptic patients in part by an increase of bradykinin B2 protein which forms heterodimer with AT1 in vivo. The heterodimer formation seems to be present not only in maternal vasculature but also in the placental constituents, because immunohistochemical stainings of bradykinin B2 were reported to be enhanced in the extravillous trophoblasts of preeclampsia cases (Corthorn et al 2006) . It is likely that AT1-mediated signalings are augmented by bradykinin B2 at uteroplacental interface which may aggravate fetoplacental microcirculation.
There is an alternative pathway that potentially enhances AT1-mediated vasoconstriction in preeclampsia. Agonistic autoimmune antibody against AT1 (AT1-AA) was detected in the sera of preeclamptic women (Wallukat et al 1999) . Although later studies have revealed that AT1-AA is also detectable in normotensive pregnant women with IUGR and Pathophysiology of placentation abnormalities in pregnancy-induced hypertension those without signifi cant complications (Walther et al 2005) , the fi nding provides us with a new insight into preeclampsia in the context of autoimmune disease. In a recent study, AT1 gene was shown to be elevated in the decidua of preeclamptic mothers and AT1-AA was increased in the fetal sera of preeclampsia cases (Herse et al 2007) . These results suggest that AT1 cascades in uteroplacental junction are aberrantly activated and that this antibody crosses the placenta and disturb fetal cardiovascular system in preeclampsia. A very recent study by Zhou and colleagues (2008) demonstrated that AT1-AA from preeclamptic women accelerated sVEGFR-1 secretion via AT1 expressed in pregnant mice in vivo, and also in human placental villous explants and immortalized human trophoblast cell line in vitro. This study shed a light on the long-standing question; whether and how RAS is implicated in the pathophysiology of PIH. They found that enhanced AT1 cascades disturbed VEGF/PlGF axis thorough calcineurin and nuclear factor of activated T-cells (NFAT) (Zhou et al 2008) . The mechanism of vascular dysfunction in PIH which involve sVEGFR-1 and AT1 cascades awaits further investigation with special attention, ie, angiogenic crosstalk between GPCR and RTK (Hobson et al 2001; Waters et al 2006; Furuya and Yonemitsu 2008) . Impaired neovascularization under excess AT1 signalings has been demonstrated in the experiments using PIH model mouse, which will be discussed later. Takimoto and colleagues (1996) generated mice by mating females expressing human angiotensinogen (hAG) with males expressing human renin (hRN), and named them Pregnancy-Associated Hypertension mice (PAH mice) ( Figure 4A ). In PAH mice, maternal blood pressure starts elevating from 13 days of gestation (E13) until delivery (E19-20) ( Figure 4A ). Systolic blood pressure at E19 in PAH mother reaches 160 mmHg whereas that in normal pregnant mouse remains around 100 mmHg (Takimoto et al 1996) . Blood pressure returns to normal level by 3 days after delivery. This elevation is attributable to the generation of excessive angiotensin I, ie, the precursor of angiotensin II, in the maternal circulation through hRN secretion from fetal side (Takimoto et al 1996) . In addition to hypertension, PAH mother shows proteinuria, cardiac hypertrophy and often convulsions. The fetus at term in PAH pregnancy shows severe IUGR, and the mean body weight of PAH fetus at E19 is about 65% of that of wild type (WT) fetus (Takimoto et al 1996; Saito et al 2004; Takimoto-Onishi et al 2005) (Figure 4B ). Both biological and physiological data demonstrated that RAS-mediated maternal hypertension beginning in the second half of gestation led PAH mother to the pathological condition that satisfi ed the criteria of PIH. Similar model was generated in rats (Bohlender et al 2000) . The hAG-transgenic female rat mated with hRNtransgenic male rat developed hypertension abruptly 10 days before delivery, and sustained this status (approximately 160 mmHg) until delivery. The course of hypertension in this model rat was different from that in PAH mouse; PAH mother showed linear elevation of blood pressure from E13 until delivery.
Preeclamptic mouse based on excessive RAS
We observed that uNK cells infi ltrated the spiral arteries suffi ciently and that trophoblasts replaced spiral arteries in the uteroplacental site of PAH placenta earlier than E13 . The results suggest that epithelial-endothelial transformation is probably taken place properly in PAH as well as in normal one. Interestingly, in a recent study using the placenta of preeclamptic rat as mentioned above, endovascular trophoblast invasion in hypertensive transgenic rat was also evident, and it was shown that the invasion was rather deeper than that in normal rat (Geusens et al 2008) . This fi nding in rat model might refl ect the variability of species-specifi c regulation of local RAS. The precise mechanism of enhanced trophoblast invasion needs further investigation.
In spite of suffi cient invasion at an early stage, maternal circulatory sVEGFR-1 in PAH mouse is significantly increased at E19. The fi nding was consistent with that of another group, in which infusion of angiotensin II signifi cantly increased circulating levels of sVEGFR-1 in pregnant mice (Zhou et al 2007) . Zhou and colleagues (2008) have further shown that the inhibition of AT1 signalings by administration of losartan or FK506 resulted in reduced sVEGFR-1. Taken together, it is highly suggested that maternal sVEGFR-1 can be elevated not only by poor placentation but also by AT1 activation in which angiotensin II, AT1-AA, and AT1-bradykinin B2 heterodimers are potentially implicated.
AT1 plays critical roles in the development of IUGR
Increased angiotensin II is generally not the case in human preeclampsia. Therefore, in the context of "pathogenesis", PAH mice may not be relevant to human PIH. On the other hand, as mentioned above, it is now widely recognized the aberrantly activated AT1 signalings in PIH patients. To clarify the signifi cance of AT1 signalings in PAH, Saito et al investigated the effects of AT1 blockade in this model (Saito et al 2004) . They generated hAG (Takimoto et al 1996) . Pathologic course of PAH pregnancy (B) Top; Whole mounts of WT fetus (left) and PAH fetus (right) at E19. Below; Placental pathology at E19. Maternal site shows diffuse fi brin deposition and apoptosis (TUNEL). In the labyrinth, the majority of ECs (CD31 in green) are poorly covered by pericytes (α-SMA in red). . Abbreviation: hANG, human angiotensinogen; hRN, human renin; AT II, angiotensin II; BP, blood pressure; WT, wild type; PAH, pregnancy-associated hypertension. Furthermore, fetal condition was signifi cantly improved ( Figure  5 ). Administration of AT1-antagonists to hAG +/+ mother also improved both maternal and fetal conditions, supporting the notion that AT1-mediated signalings play critical roles in PAH model (Saito et al 2004) . The study clearly proved that AT1-mediated signalings in maternal circulation contributed to the pathophysiology of fetal IUGR. Although AT1 and VEGFRs play pivotal roles in the pathophysiology of IUGR, it should be noted that vessel receptors are activated not only by biochemical substances. Signalings in vascular cells are also potentially controlled by shear stress and hemodynamic load (Li et al 1999; Kalluri 2003) . Mechanical force is known to act on several sensors including platelet-derived growth factor receptor (PDGFR)-β, integrins and ion channels in the vascular cells, and to modulate cellular morphology (Li and Xu 2000) . Thus, it is suggested that in PIH patients, once blood pressure starts elevating, shear stress per se accelerates unfavorable signalings in maternal circulation which contributes to placental dysfunction and IUGR development.
The process of impaired neovascularization after the onset of hypertension
Pathological examination of human PIH placenta reveals diffuse fi brin deposition and acute atherosis in uteroplacental sites, ie, mural fi brinoid necrosis of spiral arteries (Figure 6 , left). With regard to fetoplacental circulatory unit, terminal villi are poorly differentiated, so called distal villous hypoplasia (Figure 6, center) . Syncytial knots, ie, aggregation of syncytiotrophoblastic nuclei, are also noted (Figure 6 , right). It is generally thought that such changes in PIH refl ect placental hypoxia due to shallow invasion of extravillous trophoblasts at initial stage. However, it has not been answered whether acute atherosis and impaired neovascularization also occur by other predisposing factors, eg, accelerated AT1 signaling.
As mentioned above, PAH placenta shows normal-looking pseudovasculogenesis at initial stage; ie, suffi cient uNK cells infi ltration and appropriate trophoblasts invasion . It may not be surprising because at this stage the level of hRN produced from the placenta is not enough to act on hAG of maternal circulation (Takimoto et al 1996) . We investigated placental pathology, and found signifi cant atherosis with apoptotic change in uteroplacental site of PAH at E19. Time course analysis showed impaired fetoplacental vascular development and maturation after the onset of hypertension. Microvessel densities were signifi cantly low, and fetal-derived ECs were lacking for appropriate pericytes coverage and basement membrane support ( Figure 4B ) . These fi ndings indicate that placental neovascularization is potentially suppressed under maternal hypertension without the history of poor placentation. In the analysis of vasoactive molecules, some vasoactive genes were down-regulated within 24 hrs after the onset of mAT-1a −/− female mated with hRN +/+ male, the growth is markedly improved (right) (Saito et al 2004) . Abbreviations: hANG, human angiotensinogen; hRN, human renin; mAT-1a, mouse angiotensin II receptor type 1a receptor; WT, wild type; PAH, pregnancy-associated hypertension.
hypertension. Then the molecules that mediate ECs-pericytes interaction were hampered at the middle stage of hypertension . These results suggest that the fate of pathological neovascularization might be designated by early responsive genes and that following disturbance of the signalings for vessel maturation might result in abnormal fetoplacental vasculature in the terminal stage. Further studies are necessary to clarify whether the series of angiogenic disturbances are taken place in time-dependent manner one after another, or the dysfunction of each molecule is determined by the level of shear stress and/or AT1 signaling strength.
Conclusions and future prospects
As described in this review, AT1-mediated signalings are aberrantly activated in many, if not all, PIH cases. It is necessary to understand the roles of AT1 in pregnancy complications in a wide range of view. Various GPCRs including AT1 are reported to transactivate epidermal growth factor receptor (EGFR) in vitro (Prenzel et al 1999; Olivares-Reyes et al 2005) , thus it might not be surprising that AT1 and other GPCRs potentially cross-talk with VEGF/PlGF-mediated RTK signalings and contribute to sVEGFR-1 production (Furuya et al 2005; Milstien and Spiegel 2006; Dorsam and Gutkind 2007; Zhou et al 2008) . Some GPCRs such as neurokinin-B and endothelin-1 are likely to play critical roles in the pathophysiology of PIH (Page et al 2000; Ajne et al 2003) , thus they may also be involved in RTK-mediated neovascularization in the placenta.
Currently, the pathophysiology of PIH should also be investigated from artifi cial immunogenic milieu that had been unexpected in old era. Because of improved therapeutic approaches to infertility, backgrounds of PIH and IUGR have become more and more complicated. Obstetricians may face PIH cases in which the third genetic factor is involved, ie, gestational surrogacy and oocyte donation pregnancy. It is reported that the risk of PIH is increased up to 30% in oocyte donation pregnancy (Salha et al 1999) . Although maternal conditions vary among cases, it is very likely that the frequency of PIH in the women after infertility treatment will be increased.
For better understanding and management of PIH, it is necessary to investigate not only human cases but also rodent PIH models in which the mechanism of placental dysfunction and IUGR under maternal hypertension can be monitored in detail. It is also desirable to analyze therapeutic effects of targeting molecules involved in various angiogenic pathways of the placenta. If the mechanism of placental dysfunction in PIH and other IUGR-associated complications is fully elucidated, it will certainly provide more precise diseasespecifi c strategies, and contribute to more effective and safer therapies in future.
atherosis distal villous hypoplasia syncytial knots Figure 6 Pathology of human placenta in PIH. Atherosis (left), mural fi brinoid necrosis and the accumulation of macrophages; villous hypoplasia (center), decreased number of villi, with thin, poorly-branched and vascularized villi; syncytial knots (right, arrows), aggregation of syncytiotrophoblastic nuclei.
